rs267606712
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PP3PM2_SupportingPS3PS4PVS1_Moderate
This summary comes from the ClinGen Evidence Repository: The c.1008G>A (NM_004360.5) variant in CDH1is a G to non-G variant in the last nucleotide in exon 7. It is predicted to cause a loss of the donor splice site resulting in retention of intron 7 (PVS1_Moderate). This prediction is confirmed by RT-PCR cDNA demonstrating that the variant impacts splicing by producing 4 different alternatively spliced transcripts containing premature termination codons (PTC) caused by the use of cryptic donor splice sites in the intron (PS3, PMID:8127895). This variant has been reported in 4 probands/families meeting hereditary diffuse gastric cancer genetic testing criteria (PS4; PMIDs 9536098, 27730413, ClinVar SCVs: SCV000275557.6, SCV000760854.3, Internal lab contributors). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). The results from 3 in silico splicing predictors (SpliceAI, MaxEntScan, NNsplice) indicate that this variant may affect splicing by disrupting the donor splice site of intron 7 of CDH1 (PP3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PS3, PS4, PP3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10580100/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 splice_region, synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.1008G>A | p.Glu336= | splice_region_variant, synonymous_variant | 7/16 | ENST00000261769.10 | NP_004351.1 | |
CDH1 | NM_001317184.2 | c.1008G>A | p.Glu336= | splice_region_variant, synonymous_variant | 7/15 | NP_001304113.1 | ||
CDH1 | NM_001317185.2 | c.-608G>A | splice_region_variant, 5_prime_UTR_variant | 7/16 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.-812G>A | splice_region_variant, 5_prime_UTR_variant | 7/15 | NP_001304115.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDH1 | ENST00000261769.10 | c.1008G>A | p.Glu336= | splice_region_variant, synonymous_variant | 7/16 | 1 | NM_004360.5 | ENSP00000261769 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary diffuse gastric adenocarcinoma Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Jun 12, 2023 | This variant is considered likely pathogenic. mRNA analysis has demonstrated abnormal mRNA splicing occurs [PMID: 9537325, Myriad internal data]. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 13, 2021 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant is associated with altered splicing, which introduces a premature termination codon (PMID: 8127895, 18427545). The resulting mRNA is expected to undergo nonsense-mediated decay. Studies have shown that this variant alters CDH1 gene expression (PMID: 8127895). This variant has been reported in an observed in individual(s) with diffuse gastric cancer (PMID: 27730413). ClinVar contains an entry for this variant (Variation ID: 231647). This variant is not present in population databases (ExAC no frequency). This sequence change affects codon 336 of the CDH1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the CDH1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. - |
CDH1-related diffuse gastric and lobular breast cancer syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | curation | ClinGen CDH1 Variant Curation Expert Panel | Mar 25, 2024 | The c.1008G>A (NM_004360.5) variant in CDH1is a G to non-G variant in the last nucleotide in exon 7. It is predicted to cause a loss of the donor splice site resulting in retention of intron 7 (PVS1_Moderate). This prediction is confirmed by RT-PCR cDNA demonstrating that the variant impacts splicing by producing 4 different alternatively spliced transcripts containing premature termination codons (PTC) caused by the use of cryptic donor splice sites in the intron (PS3, PMID: 8127895). This variant has been reported in 4 probands/families meeting hereditary diffuse gastric cancer genetic testing criteria (PS4; PMIDs 9536098, 27730413, ClinVar SCVs: SCV000275557.6, SCV000760854.3, Internal lab contributors). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). The results from 3 in silico splicing predictors (SpliceAI, MaxEntScan, NNsplice) indicate that this variant may affect splicing by disrupting the donor splice site of intron 7 of CDH1 (PP3). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Moderate, PM2_Supporting, PS3, PS4, PP3. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 18, 2022 | The c.1008G>A pathogenic mutation (also known as p.E336E), located in coding exon 7 of the CDH1 gene, results from a G to A substitution at nucleotide position 1008. This nucleotide substitution does not change the amino acid at codon 336. However, this change occurs in the last base pair of coding exon 7, which makes it likely to have some effect on normal mRNA splicing. This alteration was previously identified in a patient with diffuse gastric cancer (Ambry internal data). It was also observed in a gastric cancer cell line originating from a patient with diffuse gastric cancer (Oda T et al. Proc. Natl. Acad. Sci. U.S.A. 1994 Mar; 91(5):1858-62). RNA analysis of this cell line showed that c.1008G>A abolishes the native donor splice site resulting in three out-of-frame transcripts (Karam R et al. Oncogene 2008 Jul; 27(30):4255-60). Internal RNA splicing analyses of c.1008G>T were consistent with those performed by Karam et al. and showed three out-of-frame transcripts: a 7 base pair insertion, a 25 base pair insertion, and an insertion of intron 7 (Ambry internal data). Additionally, a variant affecting the same nucleotide, c.1008G>T, segregated in a family affected with hereditary diffuse gastric cancer (Guilford P et al. Nature 1998 Mar; 392(6674):402-5). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at